Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) EV-to-EBITDA : -0.05 (As of Jun. 07, 2024)

Freeline Therapeutics Holdings EV-to-EBITDA Chart

Freeline Therapeutics Holdings Quarterly Data
	Dec18	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBITDA	Get a 7-Day Free Trial													0.10	0.14	0.27	0.25	0.17

Competitive Comparison of Freeline Therapeutics Holdings's EV-to-EBITDA

For the Biotechnology subindustry, Freeline Therapeutics Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Freeline Therapeutics Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Freeline Therapeutics Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Freeline Therapeutics Holdings's EV-to-EBITDA falls into.

Freeline Therapeutics Holdings EV-to-EBITDA Calculation

Freeline Therapeutics Holdings's EV-to-EBITDA for today is calculated as:

Freeline Therapeutics Holdings's current Enterprise Value is $2.99 Mil.
Freeline Therapeutics Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Freeline Therapeutics Holdings  (NAS:FRLN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Freeline Therapeutics Holdings's PE Ratio for today is calculated as:

Freeline Therapeutics Holdings's share price for today is $6.48.
Freeline Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.400.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Freeline Therapeutics Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Freeline Therapeutics Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Freeline Therapeutics Holdings (Freeline Therapeutics Holdings) Business Description